Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
NCT03134131 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2022-03-14
Summary
The objective of this expanded access program is to provide ONC201 to eligible patients with previously-treated glioma that exhibits the H3 K27M mutation and/or that is located in the midline region of the brain.
Conditions
Interventions
- DRUG
-
ONC201
ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 3 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Implantable Microdevice In Primary Brain Tumors
NCT04135807 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors
NCT00179803 ·Status: COMPLETED ·Phase: PHASE2
-
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
NCT03072134 ·Status: COMPLETED ·Phase: PHASE1
-
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies
NCT03954691 ·Status: UNKNOWN
-
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
NCT05561374 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT04732065 ·Status: RECRUITING ·Phase: PHASE1
-
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
NCT00052013 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
NCT00210314 ·Status: COMPLETED ·Phase: PHASE2
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
NCT01466686 ·Status: COMPLETED ·Phase: PHASE2
-
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
NCT06528691 ·Status: RECRUITING ·Phase: PHASE2
-
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
NCT03830151 ·Status: RECRUITING ·Phase: PHASE1
-
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
NCT01878617 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
AMG 595 First-in-Human in Recurrent Gliomas
NCT01475006 ·Status: COMPLETED ·Phase: PHASE1
-
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma
NCT03893903 ·Status: COMPLETED ·Phase: PHASE1
-
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379 ·Status: RECRUITING
-
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
NCT01975701 ·Status: COMPLETED ·Phase: PHASE2
-
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
NCT00002971 ·Status: COMPLETED ·Phase: PHASE1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
NCT03739411 ·Status: RECRUITING ·Phase: PHASE1
-
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
NCT04661384 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Expanded Access Protocol Using 131I-MIBG
NCT01590680 ·Status: AVAILABLE
-
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
NCT04219475 ·Status: SUSPENDED
-
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
NCT05588141 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
NCT02359565 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Navigating the Clinical Research Process for Glioma
NCT05958472 ·Status: NOT_YET_RECRUITING
-
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
NCT00114140 ·Status: COMPLETED ·Phase: PHASE2